Inventiva SACA

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

04 Dec 2023 13:05:00 By Nasdaq GlobeNewswire

Inventiva reports 2023 Third Quarter Financial Information¹

21 Nov 2023 13:00:00 By Nasdaq GlobeNewswire

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

06 Nov 2023 13:00:00 By Nasdaq GlobeNewswire

Inventiva reports its 2023 first-half financial results and provides a corporate update

28 Sep 2023 13:00:00 By Nasdaq GlobeNewswire

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

20 Sep 2023 13:00:00 By Nasdaq GlobeNewswire

Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

30 Aug 2023 22:30:00 By Nasdaq GlobeNewswire

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

27 Jul 2023 13:00:00 By Nasdaq GlobeNewswire

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

23 Jun 2023 23:00:00 By Nasdaq GlobeNewswire

Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

13 Jun 2023 14:00:00 By Nasdaq GlobeNewswire

Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients  

07 Jun 2023 23:30:00 By Nasdaq GlobeNewswire

Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

07 Jun 2023 13:00:00 By Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023

26 May 2023 13:00:00 By Nasdaq GlobeNewswire

Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

25 May 2023 13:00:00 By Nasdaq GlobeNewswire

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023

25 May 2023 06:50:00 By Nasdaq GlobeNewswire

Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

16 May 2023 13:00:00 By Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023

03 May 2023 23:31:00 By Nasdaq GlobeNewswire

Combined General Meeting of May 25, 2023. Availability of the preparatory documents

03 May 2023 23:30:00 By Nasdaq GlobeNewswire

Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F

30 Mar 2023 05:19:15 By Nasdaq GlobeNewswire

Inventiva reports its 2022 full-year results

29 Mar 2023 13:00:00 By Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

23 Mar 2023 14:00:00 By Nasdaq GlobeNewswire